IgG / IgM ANTIBODY RAPID TEST

For Detecting Exposure and Infection For COVID-19

MedQuest has partnered with MTJR to distribute the PCL COVID19 Rapid Gold IgG/IgM Antibody Test Kits.  The MTJR partnership details include a 40% profit sharing agreement for PCL tests sold in North and South America.

The following overview describes the PCL COVID19 Rapid Gold IgG/IgM Antibody Test Kits and how they function.

HIGH PERFORMANCE AND LOW COST DIAGNOSTIC TESTING PLATFORM

SG Cap™ Core Technology

BioChip / Microarrays - a high-performance, low cost solution for multiplex disease diagnosis
BioChip / Microarrays - a high-performance, low cost solution for multiplex disease diagnosis
  • 3D Sol-gel capturing system: Platform for diagnosis of multiple infectious diseases (Immunodiagnostics)
  • A disease marker immobilization technology that is 1,000 times more sensitive than existing technology,
 with no cross-reactions or interference

High Sensitivity

  • 3D Chip Advantage: immobilize high concentration of probes without increasing surface area
  • High sensitivity (fM level)
  • 1,000x more sensitive than existing diagnostic technology

HighSensitivity

High Specificity

  • 3D network of pores connected by larger channels
  • Size Exclusive Sol-gel › low background, high specificity
PCL COVID-19 IgG/IgM RAPID GOLD TEST

COVID-19 TEST GUIDELINE

COVID-19 IgG/IgM RAPID GOLD TEST

10 min qualitative detection of COVID-19 IgG/IgM antibody blood samples
No analyzer needed

HOW IT WORKS

RESULTS

TEST RESULTS INTERPRETATION

Result Interpretation
IgM positive / IgG negative Early infection, able to transmit infection
IgM positive / IgG positive Acute or recent infection, able to transmit infection.
IgM negative / IgG positive Infection resolved, not likely to transmit infection
IgM negative / IgG negative Either not infected or at early onset of infection when only RT-PCR test can be used to
confirm

ANALYTICAL SPECIFICITY

Cross-reactivity

Substances listed below are confirmed not to have cross-reactivity with PCL COVID-19 IgG/IgM Rapid Gold.

  • Influenza A IgM

  • Influenza B IgM

  • RSV IgM

  • Parainfluenza IgM

  • Mycoplasma pneumoniae IgM

  • Chlamydia pneumoniae IgM

Interference response

Substances listed below are confirmed not to have interference with PCL COVID-19 IgG/IgM Rapid Gold.

  • Hemoglobin

  • Bilirubin

  • Triglycerides

  • Cholesterol

  • Rheumatoid Factor

  • EDTA

  • Sodium citrate

  • Heparin Sodium

PCL COVID19 Rapid Gold IgG/IgM Test Kit Clinical Results

Performance IgM IgG Total
Sensitivity 70.6% [84/119] 87.4% [104/119] 90.8% [108/119]
Specificity 99.9% [1080/1081] 99.4% [1074/1081] 99.4% [1074/1081]

Clinical performance after seroconversion (10 days after RT-PCR confirmed) was evaluated in three different institutions in comparison with RT-PCR positive cases.